Results 231 to 240 of about 512,984 (398)

Toward Natural Limb Function: A New Era in Prosthetic Innovation

open access: yesAnnals of Neurology, EarlyView.
The past decade has witnessed groundbreaking clinical implementation of neuroprosthetic limbs driven by signals from peripheral targets (eg, nerves and muscle) and the brain to restore limb function for individuals with limb loss or impairment. In this review, we highlight recent key clinical trials in peripheral neuroprosthetic interfaces directly ...
Yucheng Tian   +4 more
wiley   +1 more source

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Tofersen is the first effective and approved therapy for superoxide dismutase 1 (SOD1)‐associated amyotrophic lateral sclerosis (ALS [SOD1‐ALS]). Following treatment with tofersen, neurofilament levels in patients' cerebrospinal fluid (CSF) and serum seem to respond earlier than clinical parameters.
Christina Steffke   +36 more
wiley   +1 more source

MOTOR DRIVER'S PALSY. [PDF]

open access: green, 1907
DonaldF. Shearer
openalex   +1 more source

Intranasal Wharton's Jelly‐Derived Mesenchymal Stem Cell Therapy, Alone or in Conjunction With Therapeutic Hypothermia, Alleviates Neonatal Hypoxic‐Ischemic Brain Injury in Mice

open access: yesAnnals of Neurology, EarlyView.
This study demonstrates that intranasal Wharton's jelly‐derived mesenchymal stem cell (WJ‐MSC) administration at 3 or 10 days post‐insult reduced the lesion size and sensorimotor impairment following neonatal hypoxic‐ischemic (HI) brain injury in mice. WJ‐MSCs expressed receptors for HI‐upregulated chemokines and migrated from the nasal cavity into the
Caroline G. M. de Theije   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy